Seizure Management in Dialysis Patients

Critical Safety Concerns

IV lorazepam formulations contain propylene glycol as a diluent, which can cause metabolic acidosis and acute kidney injury, with toxicity occurring at total daily doses as low as 1 mg/kg, according to Praxis Medical Insights 1
Serum osmol gap >10-12 mOsm/L can screen for propylene glycol accumulation, as recommended by Praxis Medical Insights 1
Propylene glycol toxicity can be easily overlooked because metabolic acidosis and kidney injury are already common in dialysis patients, highlighting the need for careful monitoring, as noted by Praxis Medical Insights 1

For a dialysis patient requiring PRN seizure management, the initial dose should be limited to 1-2 mg IV, with a 50% dose reduction based on the increased half-life and volume of distribution, as suggested by Praxis Medical Insights 1
Limiting cumulative daily doses to minimize propylene glycol exposure is crucial, with a recommended total daily dose of less than 1 mg/kg, according to Praxis Medical Insights 1

Consider alternative benzodiazepines, such as midazolam, for prolonged or frequent seizure management in renal insufficiency, as recommended by Praxis Medical Insights 1
Seizures in dialysis patients occur in approximately 3-5% of patients and are often related to dialysis disequilibrium, electrolyte shifts, or uremic encephalopathy, as reported by the American Journal of Kidney Diseases 2 and 3

Propylene glycol toxicity should not be assumed to only occur with high doses, as it can occur at 1 mg/kg/day, emphasizing the need for careful dosing, as warned by Praxis Medical Insights 1
Metabolic acidosis should not be overlooked as a potential sign of propylene glycol toxicity, as it can mimic common ICU problems, highlighting the importance of vigilant monitoring, as noted by Praxis Medical Insights 1